Optimization of Antischistosomal Chemotypes

抗血吸虫化学型的优化

基本信息

项目摘要

Schistosomiasis is a tropical parasitic disease caused by infections with flukes of the genus Schistosoma, affecting as many as 200 million individuals worldwide, with 779 million living at risk of infection. A new drug for schistosomiasis is urgently needed as praziquantel is currently the drug of last resort and the development of resistance cannot be ignored, particularly in view of its large-­scale use in many endemic. Our long-­term goal is to discover a new orally active single-­dose antischistosomal drug with activities against all parasite stages and with a novel mechanism of action. The objective of this proposal is to identify one or more antischistosomal drug development candidates. To accomplish this objective, we will optimize four promising antischistosomal chemotypes. We will also continue our investigation into the host-­mediated antischistosomal mode of action of aryl hydantoin drug candidate AR102. We propose four specific aims: 1) to synthesize and characterize target compounds; 2) to assess pharmacokinetic properties and antischistosomal activity of target compounds; 3) to further profile selected target compounds using more rigorous assays; and 4) to investigate the mode of action of drug candidate AR102. Compound design will be informed by existing SAR and will maximize structural diversity guided by prospective in silico physicochemical profiling. Based on iterative feedback from physicochemical profiling, in vitro ADME, and cytotoxicity (SA 1), ex vivo and in vivo antischistosomal activity and in vivo ADME (SA 2 and 3), new structural hypotheses will arise, and we will synthesize additional target compounds. Target compounds will progress through the various assays using clearly defined progression criteria. We suggest that this proposed research is innovative for several reasons First, the aryl hydantoins and ozonides have proven in vivo antischistosomal efficacy, but have very low ex vivo (in vitro) activity, the reverse of the usual situation where lead compounds have in vitro but no in vivo activity. Second, the azonine keto lactam chemotype and backup tricyclic imidazolidin-­4-­one compound series are examples of relatively rare medium-­ring compounds (8 to 11 atoms). Third, we seek to demarcate the unique host-­mediated mode of action of antischistosomal drug candidate AR102. The expected outcome from this work is to identify one or more antischistosomal drug development candidates effective against all parasite stages. For antischistosomal drug candidate AR102, we will define its host-­mediated antischistosomal mode of action. This proposed research is significant because a new drug would be important in the chemotherapy of drug-­resistant schistosomiasis and likely be valuable in integrated control programs to curb this parasitic disease.
血吸虫病是一种由血吸虫属吸虫感染引起的热带寄生虫病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jonathan L Vennerstrom其他文献

Jonathan L Vennerstrom的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jonathan L Vennerstrom', 18)}}的其他基金

Optimization of Antischistosomal Chemotypes
抗血吸虫化学型的优化
  • 批准号:
    8998926
  • 财政年份:
    2015
  • 资助金额:
    $ 62.56万
  • 项目类别:
Optimization of Antischistosomal Chemotypes
抗血吸虫化学型的优化
  • 批准号:
    10598486
  • 财政年份:
    2015
  • 资助金额:
    $ 62.56万
  • 项目类别:
Optimization of Antischistosomal Chemotypes
抗血吸虫化学型的优化
  • 批准号:
    8861056
  • 财政年份:
    2015
  • 资助金额:
    $ 62.56万
  • 项目类别:
Leveraging RC-12 for Radical Cure of Plasmodium Vivax
利用 RC-12 根治间日疟原虫
  • 批准号:
    8430756
  • 财政年份:
    2013
  • 资助金额:
    $ 62.56万
  • 项目类别:
Increasing the Antischistosomal Selectivity of Aryl Hydantoins
提高芳基乙内酰脲的抗血吸虫选择性
  • 批准号:
    8374010
  • 财政年份:
    2012
  • 资助金额:
    $ 62.56万
  • 项目类别:
Increasing the Antischistosomal Selectivity of Aryl Hydantoins
提高芳基乙内酰脲的抗血吸虫选择性
  • 批准号:
    8523778
  • 财政年份:
    2012
  • 资助金额:
    $ 62.56万
  • 项目类别:
Trematocidal Synthetic Perioxides
杀吸虫合成过氧化物
  • 批准号:
    7648067
  • 财政年份:
    2008
  • 资助金额:
    $ 62.56万
  • 项目类别:
Trematocidal Synthetic Perioxides
杀吸虫合成过氧化物
  • 批准号:
    7530331
  • 财政年份:
    2008
  • 资助金额:
    $ 62.56万
  • 项目类别:
METABOLIC STABILITY IN ANTIMALARIAL TETRAOXANES
抗疟四恶烷的代谢稳定性
  • 批准号:
    2076710
  • 财政年份:
    1996
  • 资助金额:
    $ 62.56万
  • 项目类别:
OXIDANTS AS SITE-SPECIFIC ANTIMALARIALS
氧化剂作为特定部位的抗疟药
  • 批准号:
    3436754
  • 财政年份:
    1989
  • 资助金额:
    $ 62.56万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.56万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 62.56万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 62.56万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 62.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 62.56万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 62.56万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 62.56万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 62.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 62.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 62.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了